Browse by Research Team

Article

Virus-reactive T cells expanded in aplastic anemia eliminate hematopoietic progenitor cells by molecular mimicry.
Ben Hamza, A. and Welters, C. and Stadler, S. and Brüggemann, M. and Dietze, K. and Brauns, O. and Brümmendorf, T.H. and Winkler, T.H. and Bullinger, L. and Blankenstein, T. and Rosenberger, L. and Leisegang, M. and Kammertöns, T. and Herr, W. and Moosmann, A. and Strobel, J. and Hackstein, H. and Dornmair, K. and Beier, F. and Hansmann, L.
Blood 143 (14): 1365-1378. 4 April 2024

HLA-C*04:09N is expressed at the cell surface and triggers peptide-specific T-cell activation.
Welters, C. and Welters, M.L. and Stadler, S. and Bullinger, L. and Strobel, J. and Hackstein, H. and Dhamodaran, A. and Blankenstein, T. and Hansmann, L.
Haematologica 109 (4): 1121-1127. April 2024

IFNγ binding to extracellular matrix prevents fatal systemic toxicity.
Kemna, J. and Gout, E. and Daniau, L. and Lao, J. and Weißert, K. and Ammann, S. and Kühn, R. and Richter, M. and Molenda, C. and Sporbert, A. and Zocholl, D. and Klopfleisch, R. and Schütz, A. and Lortat-Jacob, H. and Aichele, P. and Kammertoens, T. and Blankenstein, T.
Nature Immunology 24 (3): 414-422. March 2023

Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptors.
Immisch, L. and Papafotiou, G. and Gallarín Delgado, N. and Scheuplein, V. and Paschen, A. and Blankenstein, T. and Willimsky, G.
Frontiers in Immunology 14 : 1119498. 16 February 2023

Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa, N. and Poncette, L. and Blankenstein, T.
Journal for ImmunoTherapy of Cancer 11 (2): e006001. February 2023

Immune phenotypes and target antigens of clonally expanded bone marrow T cells in treatment-naïve multiple myeloma.
Welters, C. and Lammoglia Cobo, M.F. and Stein, C.A. and Hsu, M.T. and Ben Hamza, A. and Penter, L. and Chen, X. and Buccitelli, C. and Popp, O. and Mertins, P. and Dietze, K. and Bullinger, L. and Moosmann, A. and Blanc, E. and Beule, D. and Gerbitz, A. and Strobel, J. and Hackstein, H. and Rahn, H.P. and Dornmair, K. and Blankenstein, T. and Hansmann, L.
Cancer Immunology Research 10 (11): 1407-1419. 1 November 2022

H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2(+) patients with diffuse midline glioma.
Immisch, L. and Papafotiou, G. and Popp, O. and Mertins, P. and Blankenstein, T. and Willimsky, G.
Journal for ImmunoTherapy of Cancer 10 (10): e005535. 27 October 2022

Rapid single-cell identification of Epstein-Barr virus-specific T-cell receptors for cellular therapy.
Lammoglia Cobo, M.F. and Welters, C. and Rosenberger, L. and Leisegang, M. and Dietze, K. and Pircher, C. and Penter, L. and Gary, R. and Bullinger, L. and Takvorian, A. and Moosmann, A. and Dornmair, K. and Blankenstein, T. and Kammertöns, T. and Gerbitz, A. and Hansmann, L.
Cytotherapy 24 (8): 818-826. August 2022

IFN-γ-dependent tumor-antigen cross-presentation by lymphatic endothelial cells promotes their killing by T cells and inhibits metastasis.
Garnier, L. and Pick, R. and Montorfani, J. and Sun, M. and Brighouse, D. and Liaudet, N. and Kammertoens, T. and Blankenstein, T. and Page, N. and Bernier-Latamani, J. and Tran, N.L. and Petrova, T.V. and Merkler, D. and Scheiermann, C. and Hugues, S.
Science Advances 8 (23): eabl5162. 8 June 2022

Isolation of neoantigen-specific human T cell receptors from different human and murine repertoires.
Grunert, C. and Willimsky, G. and Peuker, C.A. and Rhein, S. and Hansmann, L. and Blankenstein, T. and Blanc, E. and Beule, D. and Keller, U. and Pezzutto, A. and Busse, A.
Cancers 14 (7): 1842. 6 April 2022

Long-term in vitro expansion ensures increased yield of central memory T cells as perspective for manufacturing challenges.
Herda, S. and Heimann, A. and Obermayer, B. and Ciraolo, E. and Althoff, S. and Ruß, J. and Grunert, C. and Busse, A. and Bullinger, L. and Pezzutto, A. and Blankenstein, T. and Beule, D. and Na, I.K.
International Journal of Cancer 148 (12): 3097-3110. 15 June 2021

Thyrotropin receptor-specific lymphocytes in adenovirus-TSHR-immunized native and human leukocyte antigen-DR3-transgenic mice and in Graves' disease patient blood.
Degen, H. and Gavvovidis, I. and Blankenstein, T. and Uhland, K. and Ungerer, M.
Thyroid 31 (6): 950-963. June 2021

In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo.
Willimsky, G. and Beier, C. and Immisch, L. and Papafotiou, G. and Scheuplein-Schlosser, V. and Goede, A. and Holzhütter, H.G. and Blankenstein, T. and Kloetzel, P.M.
eLife 10 : e62019. 20 April 2021

CD28 co-stimulus achieves superior CAR T cell effector function against solid tumors than 4-1BB co-stimulus.
Textor, A. and Grunewald, L. and Anders, K. and Klaus, A. and Schwiebert, S. and Winkler, A. and Stecklum, M. and Rolff, J. and Henssen, A.G. and Höpken, U.E. and Eggert, A. and Schulte, J.H. and Jensen, M.C. and Blankenstein, T. and Künkele, A.
Cancers 13 (5): 1050. 2 March 2021

Early life stress regulates cardiac development through an IL4-glucocorticoid signaling balance.
Apaydin, D.C. and Jaramillo, P.A.M. and Corradi, L. and Cosco, F. and Rathjen, F.G. and Kammertoens, T. and Filosa, A. and Sawamiphak, S.
Cell Reports 33 (7): 108404. 17 November 2020

Stress hormones or general well-being are not altered in immune-deficient mice lacking either T- and B- lymphocytes or Interferon gamma signaling if kept under specific pathogen free housing conditions.
Jeuthe, S. and Kemna, J. and Kemna, C.P. and Zocholl, D. and Klopfleisch, R. and Palme, R. and Kirschbaum, C. and Thoene-Reineke, C. and Kammertoens, T.
PLoS ONE 15 (9): e0239231. 30 September 2020

Identification and ranking of recurrent neo-epitopes in cancer.
Blanc, E. and Holtgrewe, M. and Dhamodaran, A. and Messerschmidt, C. and Willimsky, G. and Blankenstein, T. and Beule, D.
BMC Medical Genomics 12 : 171. 27 November 2019

SigsPack, a package for cancer mutational signatures.
Schumann, F. and Blanc, E. and Messerschmidt, C. and Blankenstein, T. and Busse, A. and Beule, D.
BMC Bioinformatics 20 (1): 450. 2 September 2019

High salt inhibits tumor growth by enhancing anti-tumor immunity.
Willebrand, R. and Hamad, I. and Van Zeebroeck, L. and Kiss, M. and Bruderek, K. and Geuzens, A. and Swinnen, D. and Côrte-Real, B.F. and Markó, L. and Lebegge, E. and Laoui, D. and Kemna, J. and Kammertoens, T. and Brandau, S. and Van Ginderachter, J.A. and Kleinewietfeld, M.
Frontiers in Immunology 10 : 1141. 4 June 2019

Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer.
Penter, L. and Dietze, K. and Ritter, J. and Lammoglia Cobo, M.F. and Garmshausen, J. and Aigner, F. and Bullinger, L. and Hackstein, H. and Wienzek-Lischka, S. and Blankenstein, T. and Hummel, M. and Dornmair, K. and Hansmann, L.
OncoImmunology 8 (6): e1586409. 24 March 2019

Interferon-γ receptor signaling in dendritic cells restrains spontaneous proliferation of CD4(+) T cells in chronic lymphopenic mice.
Knop, L. and Frommer, C. and Stoycheva, D. and Deiser, K. and Kalinke, U. and Blankenstein, T. and Kammertoens, T. and Dunay, I.R. and Schüler, T.
Frontiers in Immunology 10 : 140. 7 February 2019

Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
Poncette, L. and Chen, X. and Lorenz, F.K.M. and Blankenstein, T.
Journal of Clinical Investigation 129 (1): 324-335. 2 January 2019

Oncogene-specific T cells fail to eradicate lymphoma-initiating B cells in mice.
Hoser, D. and Schön, C. and Loddenkemper, C. and Lohneis, P. and Kühl, A.A. and Sommermann, T. and Blankenstein, T. and Willimsky, G.
Blood 132 (9): 924-934. 30 August 2018

CAR T cells with enhanced sensitivity to B cell maturation antigen for the targeting of B cell non-Hodgkin's lymphoma and multiple myeloma.
Bluhm, J. and Kieback, E. and Marino, S.F. and Oden, F. and Westermann, J. and Chmielewski, M. and Abken, H. and Uckert, W. and Höpken, U.E. and Rehm, A.
Molecular Therapy 26 (8): 1906-1920. 1 August 2018

Targeting Merkel cell carcinoma by engineered T cells specific to T-antigens of Merkel cell polyomavirus.
Gavvovidis, I. and Leisegang, M. and Willimsky, G. and Miller, N.J. and Nghiem, P. and Blankenstein, T.
Clinical Cancer Research 24 (15): 3644-3655. August 2018

ERAP1-dependent antigen cross-presentation determines efficacy of adoptive T cell therapy in mice.
Schmidt, K. and Keller, C. and Kühl, A.A. and Textor, A. and Seifert, U. and Blankenstein, T. and Willimsky, G. and Kloetzel, P.M.
Cancer Research 78 (12): 3243-3254. June 2018

Efficient non-viral T cell engineering by Sleeping Beauty minicircles diminishing DNA toxicity and miRNAs silencing the endogenous TCR.
Clauss, J. and Obenaus, M. and Miskey, C. and Ivics, Z. and Izsvák, Z. and Uckert, W. and Bunse, M.
Human Gene Therapy 29 (5): 569-584. May 2018

A transgenic dual-luciferase reporter mouse for longitudinal and functional monitoring of T cells in vivo.
Szyska, M. and Herda, S. and Althoff, S. and Heimann, A. and Russ, J. and D'Abundo, D. and Dang, T.M. and Durieux, I. and Dörken, B. and Blankenstein, T. and Na, I.K.
Cancer Immunology Research 6 (1): 110-120. January 2018

The immune system prevents recurrence of transplanted but not autochthonous antigenic tumors after oncogene inactivation therapy.
Anders, K. and Kershaw, O. and Larue, L. and Gruber, A.D. and Blankenstein, T.
International Journal of Cancer 141 (12): 2551-2561. 15 December 2017

Human TCR-MHC coevolution after divergence from mice includes increased nontemplate-encoded CDR3 diversity.
Chen, X. and Poncette, L. and Blankenstein, T.
Journal of Experimental Medicine 214 (11): 3417-3433. 6 November 2017

CTLA4 promotes Tyk2-STAT3 dependent B-cell oncogenecity.
Herrmann, A. and Lahtz, C. and Nagao, T. and Song, J.Y. and Chan, W.C. and Lee, H. and Yue, C. and Look, T. and Muelfarth, R. and Li, W. and Jenkins, K. and Williams, J. and Budde, L.E. and Forman, S.J. and Kwak, L.W. and Blankenstein, T. and Yu, H.
Cancer Research 77 (18): 5118-5128. 15 September 2017

Tumour ischaemia by interferon-γ resembles physiological blood vessel regression.
Kammertoens, T. and Friese, C. and Arina, A. and Idel, C. and Briesemeister, D. and Rothe, M. and Ivanov, A. and Szymborska, A. and Patone, G. and Kunz, S. and Sommermeyer, D. and Engels, B. and Leisegang, M. and Textor, A. and Fehling, H.J. and Fruttiger, M. and Lohoff, M. and Herrmann, A. and Yu, H. and Weichselbaum, R. and Uckert, W. and Hübner, N. and Gerhardt, H. and Beule, D. and Schreiber, H. and Blankenstein, T.
Nature 545 (7652): 98-102. 4 May 2017

Recognition but no repair of abasic site in single-stranded DNA by human ribosomal uS3 protein residing within intact 40S subunit.
Grosheva, A.S. and Zharkov, D.O. and Stahl, J. and Gopanenko, Al.V. and Tupikin, A.E. and Kabilov, M.R. and Graifer, D.M. and Karpova, G.G.
Nucleic Acids Research 45 (7): 3833-3843. 20 April 2017

Tumor-infiltrating merkel cell polyomavirus-specific T cells are diverse and associated with improved patient survival.
Miller, N.J. and Church, C.D. and Dong, L. and Crispin, D. and Fitzgibbon, M.P. and Lachance, K. and Jing, L. and Shinohara, M. and Gavvovidis, I. and Willimsky, G. and McIntosh, M. and Blankenstein, T. and Koelle, D.M. and Nghiem, P.
Cancer Immunology Research 5 (2): 137-147. February 2017

Preventing tumor escape by targeting a post-proteasomal trimming independent epitope.
Textor, A. and Schmidt, K. and Kloetzel, P.M. and Weißbrich, B. and Perez, C. and Charo, J. and Anders, K. and Sidney, J. and Sette, A. and Schumacher, T.N.M. and Keller, C. and Busch, D.H. and Seifert, U. and Blankenstein, T.
Journal of Experimental Medicine 213 (11): 2333-2348. 17 October 2016

Interleukin-7 modulates anti-tumor CD8+ T cell responses via its action on host cells.
Deiser, K. and Stoycheva, D. and Bank, U. and Blankenstein, T. and Schüler, T.
PLoS ONE 11 (7): e0159690. 22 July 2016

Thymus-derived regulatory T cells are positively selected on natural self-antigen through cognate interactions of high functional avidity.
Kieback, E. and Hilgenberg, E. and Stervbo, U. and Lampropoulou, V. and Shen, P. and Bunse, M. and Jaimes, Y. and Boudinot, P. and Radbruch, A. and Klemm, U. and Kühl, A.A. and Liblau, R. and Hoevelmeyer, N. and Anderton, S.M. and Uckert, W. and Fillatreau, S.
Immunity 44 (5): 1114-1126. 17 May 2016

Targeting human melanoma neoantigens by T cell receptor gene therapy.
Leisegang, M. and Kammertoens, T. and Uckert, W. and Blankenstein, T.
Journal of Clinical Investigation 126 (3): 854-858. 1 March 2016

Molecular contacts of ribose-phosphate backbone of mRNA with human ribosome.
Sharifulin, D.E. and Grosheva, A.S. and Bartuli, Y.S. and Malygin, A.A. and Meschaninova, M.I. and Ven'yaminova, A.G. and Stahl, J. and Graifer, D.M. and Karpova, G.G.
Biochimica et Biophysica Acta - Gene Regulatory Mechanisms 1849 (8): 930-939. August 2015

Apoptosis resistance, mitotic catastrophe, and loss of ploidy control in Burkitt lymphoma.
Chumduri, C. and Gillissen, B. and Richter, A. and Richter, A. and Milojkovic, A. and Overkamp, T. and Mueller, A. and Pott, C. and Daniel, P.T.
Journal of Molecular Medicine 93 (5): 559-572. May 2015

Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB.
Flörcken, A. and Grau, M. and Wolf, A. and Weilemann, A. and Kopp, J. and Dörken, B. and Blankenstein, T. and Pezzutto, A. and Lenz, P. and Lenz, G. and Westermann, J.
International Journal of Cancer 136 (8): 1814-1826. 15 April 2015

Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice.
Obenaus, M. and Leitão, C. and Leisegang, M. and Chen, X. and Gavvovidis, I. and van der Bruggen, P. and Uckert, W. and Schendel, D.J. and Blankenstein, T.
Nature Biotechnology 33 (4): 402-407. April 2015

Visceral leishmaniasis diagnosis and reporting delays as an obstacle to timely response actions in Nepal and India.
Boettcher, J.P. and Siwakoti, Y. and Milojkovic, A. and Siddiqui, N.A. and Gurung, C.K. and Rijal, S. and Das, P. and Kroeger, A. and Banjara, M.R.
BMC Infectious Diseases 15 (1): 43. 6 February 2015

MHCII-independent CD4(+) T cells protect injured CNS neurons via IL-4.
Walsh, J.T. and Hendrix, S. and Boato, F. and Smirnov, I. and Zheng, J. and Lukens, J.R. and Gadani, S. and Hechler, D. and Gölz, G. and Rosenberger, K. and Kammertöns, T. and Vogt, J. and Vogelaar, C. and Siffrin, V. and Radjavi, A. and Fernandez-Castaneda, A. and Gaultier, A. and Gold, R. and Kanneganti, T.D. and Nitsch, R. and Zipp, F. and Kipnis, J.
Journal of Clinical Investigation 125 (2): 699-714. 2 February 2015

Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ.
Textor, A. and Listopad, J.J. and Wührmann, L.L. and Perez, C. and Kruschinski, A. and Chmielewski, M. and Abken, H. and Blankenstein, T. and Charo, J.
Cancer Research 74 (23): 6796-6805. 1 December 2014

Misinitiation of intrathymic MART-1 transcription and biased TCR usage explain the high frequency of MART-1-specific T cells.
Pinto, S. and Sommermeyer, D. and Michel, C. and Wilde, S. and Schendel, D. and Uckert, W. and Blankenstein, T. and Kyewski, B.
European Journal of Immunology 44 (9): 2811-2821. September 2014

Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts.
Perez, C. and Jukica, A. and Listopad, J.J. and Anders, K. and Kühl, A.A. and Loddenkemper, C. and Blankenstein, T. and Charo, J.
International Journal of Cancer 137 (2): 359-371. 15 July 2014

IL-13 but not IL-4 signaling via IL-4Rα protects mice from papilloma formation during DMBA/TPA two-step skin carcinogenesis.
Rothe, M. and Quarcoo, D. and Chashchina, A.A. and Bozrova, S.V. and Qin, Z. and Nedospasov, S.A. and Blankenstein, T. and Kammertoens, T. and Drutskaya, M.S.
Cancer Medicine 2 (6): 815-825. December 2013

High-throughput identification of antigen-specific TCRs by TCR gene capture.
Linnemann, C. and Heemskerk, B. and Kvistborg, P. and Kluin, R.J.C. and Bolotin, D.A. and Chen, X. and Bresser, K. and Nieuwland, M. and Schotte, R. and Michels, S. and Gomez-Eerland, R. and Jahn, L. and Hombrink, P. and Legrand, N. and Shu, C.J. and Mamedov, I.Z. and Velds, A. and Blank, C.U. and Haanen, J.B.A.G. and Turchaninova, M.A. and Kerkhoven, R.M. and Spits, H. and Hadrup, S.R. and Heemskerk, M.H.M. and Blankenstein, T. and Chudakov, D.M. and Bendle, G.M. and Schumacher, T.N.M.
Nature Medicine 19 (11): 1534-1541. November 2013

Vaccine-instructed intratumoral IFN-γ enables regression of autochthonous mouse prostate cancer in allogeneic T cell transplantation.
Hess Michelini, R. and Manzo, T. and Sturmheit, T. and Basso, V. and Rocchi, M. and Freschi, M. and Listopad, J.J. and Blankenstein, T. and Bellone, M. and Mondino, A.
Cancer Research 73 (15): 4641-4652. 1 August 2013

Generation of transgenic mice with megabase-sized human yeast artificial chromosomes by yeast spheroplast-embryonic stem cell fusion.
Li, L. and Blankenstein, T.
Nature Protocols 8 (8): 1567-1582. August 2013

Fibroblast-specific protein 1/S100A4-positive cells prevent carcinoma through collagen production and encapsulation of carcinogens.
Zhang, J and Chen, L and Liu, X and Kammertoens, T. and Blankenstein, T. and Qin, Z.
Cancer Research 73 (9): 2770-2781. 1 May 2013

Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer.
Schmidt, K. and Zilio, S. and Schmollinger, J.C. and Bronte, V. and Blankenstein, T. and Willimsky, G.
Blood 121 (10): 1740-1748. 7 March 2013

Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.
Willimsky, G. and Schmidt, K. and Loddenkemper, C. and Gellermann, J. and Blankenstein, T.
Journal of Clinical Investigation 123 (3): 1032-1043. 1 March 2013

High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination.
Pohla, H. and Buchner, A. and Stadlbauer, B. and Frankenberger, B. and Stevanovic, S. and Walter, S. and Frank, R. and Schwachula, T. and Olek, S. and Kopp, J. and Willimsky, G. and Stief, C.G. and Hofstetter, A. and Pezzutto, A. and Blankenstein, T. and Oberneder, R. and Schendel, D.J.
Molecular Medicine 18 : 1499-1508. 8 February 2013

Fas expression by tumor stroma is required for cancer eradication.
Listopad, J.J. and Kammertoens, T. and Anders, K. and Silkenstedt, B. and Willimsky, G. and Schmidt, K. and Kuehl, A.A. and Loddenkemper, C. and Blankenstein, T.
Proceedings of the National Academy of Sciences of the United States of America 110 (6): 2276-2281. 5 February 2013

Molecular pathways: comparing the effects of drugs and T cells to effectively target oncogenes.
Anders, K. and Blankenstein, T.
Clinical Cancer Research 19 (2): 320-326. 15 January 2013

Differences in serum cytokine levels between wild type mice and mice with a targeted mutation suggests necessity of using control littermates.
Briesemeister, D. and Friese, C. and Isern, C.C. and Dietz, E. and Blankenstein, T. and Thoene-Reineke, C. and Kammertoens, T.
Cytokine 60 (3): 626-633. December 2012

Spontaneous and therapy-induced T cell responses to cancer.
Blankenstein, T.
Arzneimittelforschung 62 (1): S9. November 2012

B-cells and IL-4 promote methylcholanthrene-induced carcinogenesis but there is no evidence for a role of T/NKT-cells and their effector molecules (Fas-ligand, TNF-α, perforin).
Kammertoens, T. and Qin, Z. and Briesemeister, D. and Bendelac, A. and Blankenstein, T.
International Journal of Cancer 131 (7): 1499-1508. 1 October 2012

Depot formation of doxycycline impairs Tet-regulated gene expression in vivo.
Anders, K. and Buschow, C. and Charo, J. and Blankenstein, T.
Transgenic Research 21 (5): 1099-1107. October 2012

A novel MCPH1 isoform complements the defective chromosome condensation of human MCPH1-deficient cells.
Gavvovidis, I. and Rost, I. and Trimborn, M. and Kaiser, F.J. and Purps, J. and Wiek, C. and Hanenberg, H. and Neitzel, H. and Schindler, D.
PLoS ONE 7 (8): e40387. 30 August 2012

The determinants of tumour immunogenicity.
Blankenstein, T. and Coulie, P.G. and Gilboa, E. and Jaffee, E.M.
Nature Reviews Cancer 12 (4): 307-313. April 2012

Stromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in mice.
Gerbitz, A. and Sukumar, M. and Helm, F. and Wilke, A. and Friese, C. and Fahrenwaldt, C. and Lehmann, F.M. and Loddenkemper, C. and Kammertoens, T. and Mautner, J. and Schmitt, C.A. and Blankenstein, T. and Bornkamm, G.W.
PLoS ONE 7 (3): e34552. 30 March 2012

Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer.
Anders, K. and Buschow, C. and Herrmann, A. and Milojkovic, A. and Loddenkemper, C. and Kammertoens, T. and Daniel, P. and Yu, H. and Charo, J. and Blankenstein, T.
Cancer Cell 20 (6): 755-767. 13 December 2011

Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors.
Charo, J. and Perez, C. and Buschow, C. and Jukica, A. and Czeh, M. and Blankenstein, T.
European Journal of Immunology 41 (11): 3187-3197. November 2011

The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed.
Popovic, J. and Li, L.P. and Kloetzel, P.M. and Leisegang, M. and Uckert, W. and Blankenstein, T.
Blood 118 (4): 946-954. 28 July 2011

Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study.
Westermann, J. and Floercken, A. and Willimsky, G. and van Lessen, A. and Kopp, J. and Takvorian, A. and Joehrens, K. and Lukowsky, A. and Schoenemann, C. and Sawitzki, B. and Pohla, H. and Frank, R. and Doerken, B. and Schendel, D.J. and Blankenstein, T. and Pezzutto, A.
Gene Therapy 18 (4): 354-363. April 2011

Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis.
Briesemeister, D. and Sommermeyer, D. and Loddenkemper, C. and Loew, R. and Uckert, W. and Blankenstein, T. and Kammertoens, T.
International Journal of Cancer 128 (2): 371-378. 15 January 2011

The immune response to sporadic colorectal cancer in a novel mouse model.
Czeh, M. and Loddenkemper, C. and Shalapour, S. and Schoen, C. and Robine, S. and Goldscheid, E. and Stein, H. and Schueler, T. and Willimsky, G. and Blankenstein, T.
Oncogene 29 (50): 6591-6602. 16 December 2010

Heat shock factor 1 ameliorates proteotoxicity in cooperation with the transcription factor NFAT.
Hayashida, N. and Fujimoto, M. and Tan, K. and Prakasam, R. and Shinkawa, T. and Li, L. and Ichikawa, H. and Takii, R. and Nakai, A.
EMBO Journal 29 (20): 3459-3469. 20 October 2010

Commensal microflora and interferon-gamma promote steady-state interleukin-7 production in vivo.
Shalapour, S. and Deiser, K. and Sercan, O. and Tuckermann, J. and Minnich, K. and Willimsky, G. and Blankenstein, T. and Haemmerling, G.J. and Arnold, B. and Schueler, T.
European Journal of Immunology 40 (9): 2391-2400. September 2010

Transgenic mice with a diverse human T cell antigen receptor repertoire.
Li, L.P. and Lampert, J.C. and Chen, X. and Leitao, C. and Popovic, J. and Mueller, W. and Blankenstein, T.
Nature Medicine 16 (9): 1029-1034. September 2010

Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.
Norell, H. and Poschke, I. and Charo, J. and Wei, W.Z. and Erskine, C. and Piechocki, M.P. and Knutson, K.L. and Bergh, J. and Lidbrink, E. and Kiessling, R.
Journal of Translational Medicine 8 (1): 53. 7 June 2010

T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
Leisegang, M. and Turqueti-Neves, A. and Engels, B. and Blankenstein, T. and Schendel, D.J. and Uckert, W. and Noessner, E.
Clinical Cancer Research 16 (8): 2333-2343. 15 April 2010

In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance.
Buschow, C. and Charo, J. and Anders, K. and Loddenkemper, C. and Jukica, A. and Alsamah, W. and Perez, C. and Willimsky, G. and Blankenstein, T.
Journal of Immunology 184 (6): 2930-2938. 15 March 2010

Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia.
Shalapour, S. and Eckert, C. and Seeger, K. and Pfau, M. and Prada, J. and Henze, G. and Blankenstein, T. and Kammertoens, T.
Journal of Molecular Medicine 88 (3): 249-265. March 2010

Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma.
Buchner, A. and Pohla, H. and Willimsky, G. and Frankenberger, B. and Frank, R. and Baur-Melnyk, A. and Siebels, M. and Stief, C.G. and Hofstetter, A. and Kopp, J. and Pezzutto, A. and Blankenstein, T. and Oberneder, R. and Schendel, D.J.
Human Gene Therapy 21 (3): 285-297. March 2010

Adaptive peripheral immune response increases proliferation of neural precursor cells in the adult hippocampus.
Wolf, S.A. and Steiner, B. and Wengner, A.M. and Lipp, M. and Kammertoens, T. and Kempermann, G.
FASEB Journal 23 (9): 3121-3128. September 2009

Making and circumventing tolerance to cancer.
Kammertoens, T. and Blankenstein, T.
European Journal of Immunology 39 (9): 2345-2353. September 2009

HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.
Vertuani, S. and Triulzi, C. and Roos, A.K. and Charo, J. and Norell, H. and Lemonnier, F. and Pisa, P. and Seliger, B. and Kiessling, R.
Cancer Immunology Immunotherapy 58 (5): 653-664. May 2009

CD4-positive T lymphocytes provide a neuroimmunological link in the control of adult hippocampal neurogenesis.
Wolf, S.A. and Steiner, B. and Akpinarli, A. and Kammertoens, T. and Nassenstein, C. and Braun, A. and Blankenstein, T. and Kempermann, G.
Journal of Immunology 182 (7): 3979-3984. 1 April 2009

Positioning of subdomain IIId and apical loop of domain II of the hepatitis C IRES on the human 40S ribosome.
Babaylova, E. and Graifer, D. and Malygin, A. and Stahl, J. and Shatsky, I. and Karpova, G.
Nucleic Acids Research 37 (4): 1141-1151. March 2009

Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.
Kruschinski, A. and Moosmann, A. and Poschke, I. and Norell, H. and Chmielewski, M. and Seliger, B. and Kiessling, R. and Blankenstein, T. and Abken, H. and Charo, J.
Proceedings of the National Academy of Sciences of the United States of America 105 (45): 17481-17486. 11 November 2008

Protein S3 fragments neighboring mRNA during elongation and termination of translation on the human ribosome.
Khairulina, Y.S. and Molotkov, M.V. and Bulygin, K.N. and Graifer, D.M. and Ven’yaminova, A.G. and Frolova, L.Y. and Stahl, J. and Karpova, G.G.
Russian Journal of Bioorganic Chemistry 34 (6): 691-697. November 2008

SV40 large T antigen-transformed human primary normal and cancerous mammary epithelial cells are phenotypically similar but can be distinguished in 3D culture with selection medium.
Li, L.P. and Willimsky, G. and Seitz, S. and Xu, Y. and Li, Y. and Schwarz, L.E. and Schlag, P.M. and Blankenstein, T.
International Journal of Cancer 123 (7): 1516-1525. 1 October 2008

Ablation of TNF or lymphotoxin signaling and the frequency of spontaneous tumors in p53-deficient mice.
Kuprash, D.V. and Qin, Z. and Ito, D. and Grivennikov, S.I. and Abe, K. and Drutskaya, L.N. and Blankenstein, T. and Nedospasov, S.A.
Cancer Letters 268 (1): 70-75. 8 September 2008

Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness.
Willimsky, G. and Czeh, M. and Loddenkemper, C. and Gellermann, J. and Schmidt, K. and Wust, P. and Stein, H. and Blankenstein, T.
Journal of Experimental Medicine 205 (7): 1687-1700. 7 July 2008

A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer.
Kieback, E. and Charo, J. and Sommermeyer, D. and Blankenstein, T. and Uckert, W.
Proceedings of the National Academy of Sciences of the United States of America 105 (2): 623-628. 15 January 2008

Neuroimmune crosstalk in asthma: dual role of the neurotrophin receptor p75NTR.
Nassenstein, C. and Kammertoens, T. and Veres, T.Z. and Uckert, W. and Spies, E. and Fuchs, B. and Krug, N. and Braun, A.
Journal of Allergy and Clinical Immunology 120 (5): 1089-1096. November 2007

Dual T cell receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity.
Weinhold, M. and Sommermeyer, D. and Uckert, W. and Blankenstein, T.
Journal of Immunology 179 (8): 5534-5542. 15 October 2007

In vivo splenic CD11c cells downregulate CD4 T-cell response thereby decreasing systemic immunity to gene-modified tumour cell vaccine.
Cayeux, S. and Bukarica, B. and Buschow, C. and Charo, J. and Bunse, M. and Doerken, B. and Blankenstein, T.
Gene Therapy 14 (20): 1481-1491. October 2007

IL-10 controls ultraviolet-induced carcinogenesis in mice.
Loser, K. and Apelt, J. and Voskort, M. and Mohaupt, M. and Balkow, S. and Schwarz, T. and Grabbe, S. and Beissert, S.
Journal of Immunology 179 (1): 365-371. 1 July 2007

Tumor necrosis factor receptor 2-mediated tumor suppression is nitric oxide dependent and involves angiostasis.
Zhao, X. and Mohaupt, M. and Jiang, J. and Liu, S. and Li, B. and Qin, Z.
Cancer Research 67 (9): 4443-4450. 1 May 2007

Active MAC-1 (CD11b/CD18) on DC is inhibitory for full T cell activation.
Varga, G. and Balkow, S. and Wild, M.K. and Stadtbaeumer, A. and Krummen, M. and Rothoeft, T. and Higuchi, T. and Beissert, S. and Wethmar, K. and Scharffetter-Kochanek, K. and Vestweber, D. and Grabbe, S.
Blood 109 (2): 661-669. 15 January 2007

T cell homing to tumors detected by 3D-coordinated positron emission tomography and magnetic resonance imaging.
Agger, R. and Petersen, M.S. and Petersen, C.C. and Hansen, S.B. and Stodkilde-Jorgensen, H. and Skands, U. and Blankenstein, T. and Andersen, T.E. and Hulgaard, E.F. and Jorgensen, J.T. and Marqversen, J. and Gundersen, H.J. and Hokland, M.E.
Journal of Immunotherapy 30 (1): 29-39. January 2007

Designer T cells by T cell receptor replacement.
Sommermeyer, D. and Neudorfer, J. and Weinhold, M. and Leisegang, M. and Engels, B. and Noessner, E. and Heemskerk, M.H. and Charo, J. and Schendel, D.J. and Blankenstein, T. and Bernhard, H. and Uckert, W.
European Journal of Immunology 36 (11): 3052-3059. November 2006

Migration of immature mouse DC across resting endothelium is mediated by ICAM-2 but independent of beta2-integrins and murine DC-SIGN homologues.
Wethmar, K. and Helmus, Y. and Luehn, K. and Jones, C. and Laskowska, A. and Varga, G. and Grabbe, S. and Lyck, R. and Engelhardt, B. and Bixel, M.G. and Butz, S. and Loser, K. and Beissert, S. and Ipe, U. and Vestweber, D. and Wild, M.K.
European Journal of Immunology 36 (10): 2781-2794. October 2006

Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.
Willimsky, G. and Blankenstein, T.
Nature 437 (7055): 141-146. 1 September 2005

Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells.
Frankenberger, B. and Regn, S. and Geiger, C. and Noessner, E. and Falk, C.S. and Pohla, H. and Javorovic, M. and Silberzahn, T. and Wilde, S. and Buchner, A. and Siebels, M. and Oberneder, R. and Willimsky, G. and Pezzutto, A. and Blankenstein, T. and Schendel, D.J.
World Journal of Urology 23 (3): 166-174. 5 July 2005

Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes.
Engels, B. and Noessner, E. and Frankenberger, B. and Blankenstein, T. and Schendel, D.J. and Uckert, W.
Human Gene Therapy 16 (7): 799-810. 1 July 2005

Gentherapie mit T-Zellrezeptor modifizierten Zellen.
Uckert, W. and Blankenstein, T.
BioForum 28 (3): 27-30. 20 May 2005

CY15, a malignant histiocytic tumor that is phenotypically similar to immature dendritic cells.
Kammertoens, T. and Willebrand, R. and Erdmann, B. and Li, L. and Li, Y. and Engels, B. and Uckert, W. and Blankenstein, T.
Cancer Research 65 : 2560-2564. 1 January 2005

Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.
Roos, A.K. and Pavlenko, M. and Charo, J. and Egevad, L. and Pisa, P.
Prostate 62 (3): 217-223. 1 January 2005

Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.
Frankenberger, B. and Pohla, H. and Noessner, E. and Willimsky, G. and Papier, B. and Pezzutto, A. and Kopp, J. and Oberneder, R. and Blankenstein, T. and Schendel, D.J.
Clinical Cancer Research 11 : 1733-1742. 1 January 2005

Necrotic death but not irradiation abolishes costimulation of T-cell effector functions and survival by CD80-expressing tumor cells.
Staerck, L. and Scholz, C. and Blankenstein, T. and Doerken, B. and Daniel, P.T.
International Journal of Cancer 116 (1): 78-86. 1 January 2005

Tumor-induced antibodies resemble the response to tissue damage.
Preiss, S. and Kammertoens, T. and Lampert, C. and Willimsky, G. and Blankenstein, T.
International Journal of Cancer 115 (3): 456-462. 1 January 2005

CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions.
Ohl, L. and Mohaupt, M. and Czeloth, N. and Hintzen, G. and Kiafard, Z. and Zwirner, J. and Blankenstein, T. and Henning, G. and Foerster, R.
Immunity 21 (2): 279-288. 1 August 2004

Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors.
Gladow, M. and Uckert, W. and Blankenstein, T.
European Journal of Immunology 34 (7): 1882-1891. 1 July 2004

A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and transporter associated with antigen processing 1/2 in human melanoma cells.
Kurte, M. and Lopez, M. and Aguirre, A. and Escobar, A. and Aguillon, J.C. and Charo, J. and Larsen, C.G. and Kiessling, R. and Salazar-Onfray, F.
Journal of Immunology 173 (3): 1731-1737. 1 January 2004

CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells.
Lindencrona, J.A. and Preiss, S. and Kammertoens, T. and Schueler, T. and Piechocki, M. and Wei, W.Z. and Seliger, B. and Blankenstein, T. and Kiessling, R.
International Journal of Cancer 109 (2): 259-264. 1 January 2004

Establishment of early lymphoid organ infrastructure in transplanted tumors mediated by local production of lymphotoxin alpha and in the combined absence of functional B and T cells.
Kim, H.J. and Kammertoens, T. and Janke, M. and Schmetzer, O. and Qin, Z. and Berek, C. and Blankenstein, T.
Journal of Immunology 172 (7): 4037-4047. 1 January 2004

Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization.
Westermann, J. and Nguyen-Hoai, T. and Mollweide, A. and Richter, G. and Schmetzer, O. and Kim, H.J. and Blankenstein, T. and Doerken, B. and Pezzutto, A.
Gene Therapy 11 (13): 1048-1056. 1 January 2004

Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.
Stelljes, M. and Strothotte, R. and Pauels, H.G. and Poremba, C. and Milse, M. and Specht, C. and Albring, J. and Bisping, G. and Scheffold, C. and Kammertoens, T. and Oelmann, E. and Silling, G. and Berdel, W.E. and Kienast, J.
Blood 104 (4): 1210-1216. 1 January 2004

Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-γ pathway but not IL-12 or IL-18.
Wu, T.H. and Pabin, C.N. and Qin, Z.H. and Blankenstein, T. and Philip, M. and Dignam, J. and Schreiber, K. and Schreiber, H.
Journal of Immunology 172 (5): 3243-3251. 1 January 2004

Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes.
Muehlebach, M.D. and Schmitt, I. and Steidl, S. and Stitz, J. and Schweizer, M. and Blankenstein, T. and Cichutek, K. and Uckert, W.
Journal of Molecular Medicine 81 (12): 801-810. December 2003

Tumor rejection by modulation of tumor stromal fibroblasts.
Schueler, T. and Koernig, S. and Blankenstein, T.
Journal of Experimental Medicine 198 (10): 1487-1493. 17 November 2003

Retroviral vectors for high-level transgene expression in T lymphocytes.
Engels, B. and Cam, H. and Schueler, T. and Indraccolo, S. and Gladow, M. and Baum, C. and Blankenstein, T. and Uckert, W.
Human Gene Therapy 14 (12): 1155-1168. 10 August 2003

Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells.
Schueler, T. and Blankenstein, T.
Journal of Immunology 170 (9): 4427-4431. 1 May 2003

Nicotine strongly activates dendritic cell-mediated adaptive immunity - Potential role for progression of atherosclerotic lesions.
Aicher, A. and Heeschen, C. and Mohaupt, M. and Cooke, J.P. and Zeiher, A.M. and Dimmeler, S.
Circulation 107 (4): 604-611. 4 February 2003

Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice.
Lange, K. and Uckert, W. and Blankenstein, T. and Nadrowitz, R. and Bittner, C. and Renauld, J.C. and van Snick, J. and Feller, A.C. and Merz, H.
Oncogene 22 (4): 517-527. 30 January 2003

A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8T cells.
Qin, Z.H. and Schwartzkopff, J. and Pradera, F. and Kammertoens, T. and Seliger, B. and Pircher, H. and Blankenstein, T.
Cancer Research 63 (14): 4095-4100. 1 January 2003

Die Ueberexpression von NPM-ALK in haematopoietischen Stammzellen induziert verschiedene maligne Non-Hodgkin-Lymphome in der IL-9 transgenen Maus [Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice].
Merz, H. and Lange, K. and Nadrowitz, R. and Uckert, W. and Blankenstein, T. and Feller, A.C.
Verhandlungen der Deutschen Gesellschaft fuer Pathologie 87 : 224-231. 1 January 2003

Adenoviral transduction of tumor cells induces apoptosis in co-cultured T lymphocytes.
Scholz, C. and Staerck, L. and Willimsky, G. and Blankenstein, T. and Doerken, B. and Daniel, P.T.
Gene Therapy 9 (21): 1438-1446. November 2002

Naive CD8+ but not CD4+ T cells induce maturation of dendritic cells.
Schueler, T. and Blankenstein, T.
Journal of Molecular Medicine 80 (8): 533-541. August 2002

Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction.
Qin, Z. and Kim, H.J. and Hemme, J. and Blankenstein, T.
Journal of Experimental Medicine 195 (11): 1479-1490. 3 June 2002

Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors.
Qin, Z. and Harders, C. and Cao, X. and Huber, C. and Blankenstein, T. and Seliger, B.
Cancer Research 62 (10): 2856-2860. 15 May 2002

Generation of tumor-associated cytotoxic T lymphocytes requires interleukin 4 from CD8+ T cells.
Schueler, T. and Kammertoens, T. and Preiss, S. and Debs, P. and Noben-Trauth, N. and Blankenstein, T.
Journal of Experimental Medicine 194 (12): 1767-1775. 17 December 2001

Tumor rejection by disturbing tumor stroma cell interactions.
Ibe, S. and Qin, Z.H. and Schueler, T. and Preiss, S. and Blankenstein, T.
Journal of Experimental Medicine 194 (11): 1549-1559. 3 December 2001

The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2.
Michelsen, K.S. and Aicher, A. and Mohaupt, M. and Hartung, T. and Dimmeler, S. and Kirschning, C.J. and Schumann, R.R.
Journal of Biological Chemistry 276 (28): 25680-25686. 13 July 2001

Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay.
Becker, C. and Pohla, H. and Frankenberger, B. and Schueler, T. and Assenmacher, M. and Schendel, D.J. and Blankenstein, T.
Nature Medicine 7 (10): 1159-1162. 1 January 2001

Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells.
Seliger, B. and Wollscheid, U. and Momburg, F. and Blankenstein, T. and Huber, C.
Cancer Research 61 : 1095-1099. 1 January 2001

Decreased generation of anti-tumor immunity after intrasplenic immunization.
Cayeux, S. and Qin, Z.H. and Doerken, B. and Blankenstein, T.
European Journal of Immunology 31 (5): 1392-1399. 1 January 2001

Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function.
Yun, T.J. and Tallquist, M.D. and Aicher, A. and Rafferty, K.L. and Marshall, A.J. and Moon, J.J. and Ewings, M.K. and Mohaupt, M. and Herring, S.W. and Clark, E.A.
Journal of Immunology 166 : 1482-1491. 1 January 2001

Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse.
Schendel, D.J. and Frankenberger, B. and Jantzer, P. and Cayeux, S. and Noessner, E. and Willimsky, G. and Maget, B. and Pohla, H. and Blankenstein, T.
Gene Therapy 7 (23): 2007-2014. 1 December 2000

Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin.
Seliger, B. and Wollscheid, U. and Momburg, F. and Blankenstein, T. and Huber, C.
Tissue Antigens 56 (4): 327-336. 1 October 2000

CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNgamma receptor expression by nonhematopoietic cells.
Qin, Z.H. and Blankenstein, T.
Immunity 12 (6): 677-686. 1 June 2000

Allogeneic vaccination for renal cell carcinoma: development and monitoring.
Pohla, H. and Frankenberger, B. and Stadlbauer, B. and Oberneder, R. and Hofstetter, A. and Willimsky, G. and Pezzutto, A. and Doerken, B. and Blankenstein, T. and Schendel, D.J.
Bone Marrow Transplantation 25 Suppl. 2 (3332): S83-S87. 1 May 2000

Bcr/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia.
Westermann, J. and Kopp, J. and Koerner, I. and Richter, G. and Qin, Z. and Blankenstein, T. and Doerken, B. and Pezzutto, A.
Bone Marrow Transplantation 25 Suppl. 2 (3332): S46-S49. 1 May 2000

Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine.
Kammertoens, T. and Gelbmann, W. and Karle, P. and Alton, K. and Saller, R. and Salmons, B. and Guenzburg, W.H. and Uckert, W.
Cancer Gene Therapy 7 (4): 629-636. 1 April 2000

Interleukin-7/B7.1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors.
Willimsky, G. and Blankenstein, T.
Cancer Research 60 (3): 685-692. 1 February 2000

Efficient gene transfer into primary human CD8+ T lymphocytes by MuLV-10A1 retrovirus pseudotype.
Uckert, W. and Becker, C. and Gladow, M. and Klein, D. and Kammertoens, T. and Pedersen, L. and Blankenstein, T.
Human Gene Therapy 11 (7): 1005-1014. 1 January 2000

Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1.
Stitz, J. and Buchholz, C.J. and Engelstaedter, M. and Uckert, W. and Bloemer, U. and Schmitt, I. and Cichutek, K.
Virology 273 (1): 16-20. 1 January 2000

MLV-10A1 retrovirus pseudotype efficiently transduces primary human CD4+ T lymphocytes.
Gladow, M. and Becker, C. and Blankenstein, T. and Uckert, W.
Journal of Gene Medicine 2 (6): 409-415. 1 January 2000

Mitochondrial amplification of death signals determines thymidine kinase/ ganciclovir-triggered activation of apoptosis.
Beltinger, C. and Fulda, S. and Kammertoens, T. and Uckert, W. and Debatin, K.M.
Cancer Research 60 (12): 3212-3217. 1 January 2000

Modulation of moloney leukemia virus long terminal repeat transcriptionalactivity by the murine CD4 silencer in retroviral vectors.
Indraccolo, S. and Minuzzo, S. and Habeler, W. and Zamarchi, R. and Fregonese, A. and Guenzburg, W.H. and Salmons, B. and Uckert, W. and Chieco-Bianchi, L. and Amadori, A.
Virology 276 : 83-92. 1 January 2000

Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases.
Beltinger, C. and Fulda, S. and Kammertoens, T. and Meyer, E. and Uckert, W. and Debatin, K.M.
Proceedings of the National Academy of Sciences of the United States of America 96 : 8699-8704. 20 July 1999

T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice.
Schueler, T. and Qin, Z. and Ibe, S. and Noben-Trauth, N. and Blankenstein, T.
Journal of Experimental Medicine 189 (5): 803-810. 1 March 1999

Direct and indirect T cell priming by dendritic cell vaccines.
Cayeux, S. and Richter, G. and Becker, C. and Pezzutto, A. and Doerken, B. and Blankenstein, T.
European Journal of Immunology 29 : 225-234. 1 January 1999

Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-11.
Petersson, M. and Charo, J. and Salazar-Onfray, F. and Noffz, G. and Mohaupt, M. and Qin, Z.H. and Klein, G. and Blankenstein, T. and Kiessling, R.
Journal of Immunology 161 : 2099-2105. 1 September 1998

Interleukin 4 gene-defective mice reconstituted with wild-type bone marrow fail to produce normal immunoglobulin E levels.
Lange, C. and Schueler, T. and Blankenstein, T.
Journal of Experimental Medicine 187 (9): 1487-1493. 4 May 1998

B cells inhibit induction of T cell-dependent tumor immunity.
Qin, Z.H. and Richter, G. and Schueler, T. and Ibe, S. and Cao, X.T. and Blankenstein, T.
Nature Medicine 4 : 627-630. 1 January 1998

Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo.
Uckert, W. and Kammertoens, T. and Haack, K. and Qin, Z. and Gebert, J. and Schendel, D.J. and Blankenstein, T.
Human Gene Therapy 9 : 855-865. 1 January 1998

Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors.
Noffz, G. and Qin, Z.H. and Kopf, M. and Blankenstein, T.
Journal of Immunology 160 : 345-350. 1 January 1998

RNA levels of human retrovirus receptors Pit1 and Pit2 do not correlate with infectibility by three retroviral vector pseudotypes.
Uckert, W. and Willimsky, G. and Pedersen, F.S. and Blankenstein, T. and Pedersen, L.
Human Gene Therapy 9 : 2619-2627. 1 January 1998

Retroviral B7.1 gene transfer in cancer cells protects cytotoxic T cells from deletion by "veto" apoptosis.
Daniel, P.T. and Kroidl, A. and Cayeux, S. and Scholz, C. and Sturm, I. and Blankenstein, T. and Pezzutto, A. and Doerken, B.
Advances in Experimental Medicine and Biology 451 : 265-276. 1 January 1998

Retroviral interleukin-7 gene transfer into human dendritic cells enhances T cell activation.
Westermann, J. and Aicher, A. and Qin, Z. and Cayeux, S. and Daemen, K. and Blankenstein, T. and Doerken, B. and Pezzutto, A.
Gene Therapy 5 : 264-271. 1 January 1998

Strong immunogenic potential of a B7 retroviral expression vector: Generation of HLA-B7-restricted CTL response against selectable marker genes.
Jung, D. and Jaeger, E. and Cayeux, S. and Blankenstein, T. and Hilmes, C. and Karbach, J. and Moebius, U. and Knuth, A. and Huber, C. and Seliger, B.
Human Gene Therapy 9 : 53-62. 1 January 1998

Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis.
Daniel, P.T. and Kroidl, A. and Cayeux, S. and Bargou, R.C. and Blankenstein, T. and Doerken, B.
Journal of Immunology 159 (8): 3808-3815. 15 October 1997

Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte- macrophage colony-stimulating factor gene-modified tumor cells.
Qin, Z. and Noffz, G. and Mohaupt, M. and Blankenstein, T.
Journal of Immunology 159 (2): 770-776. 15 July 1997

Down regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10.
Salazar-Onfray, F. and Charo, J. and Petersson, M. and Freland, S. and Noffz, G. and Qin, Z.H. and Blankenstein, T. and Ljunggren, H.G. and Kiessling, R.
Journal of Immunology 159 : 3195-3202. 1 January 1997

Influence of gene modified (IL 7, IL 4, and B7) tumor cell vaccines on tumor antigen presentation.
Cayeux, S. and Richter, G. and Noffz, G. and Doerken, B. and Blankenstein, T.
Journal of Immunology 158 : 2834-2841. 1 January 1997

Lack of correlation between rejection of tumor cells co-expressing interleukin 2 and B7.1 and vaccine efficiency.
Cayeux, S. and Richter, G. and Becker, C. and Beck, C. and Aicher, A. and Pezzutto, A. and Doerken, B. and Blankenstein, T.
European Journal of Immunology 27 : 1657-1662. 1 January 1997

Loss of retroviral gene expression in bone marrow reconstituted mice correlates with down regulation of gene expression in long term culture initiating cells.
Lange, C. and Blankenstein, T.
Gene Therapy 4 : 303-308. 1 January 1997

Regulated gene expression after retroviral vector-mediated delivery of cancer-relevant therapeutic genes.
Guenzburg, W.H. and Karle, P. and Mrochen, S. and Sparmann, G. and Saller, R. and Klein, D. and Uckert, W. and Salmons, B.
Recent Results in Cancer Research 144 : 116-126. 1 January 1997

Successful retroviral mediated transduction of a receptor gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells.
Aicher, A. and Westermann, J. and Cayeux, S. and Willimsky, G. and Daemen, K. and Blankenstein, T. and Uckert, W. and Doerken, B. and Pezzutto, A.
Experimental Hematology 25 : 39-44. 1 January 1997

Transient expression of SV 40 large T antigen by Cre/LoxP mediated site specific deletion in primary human tumor cells.
Li, L.P. and Schlag, P.M. and Blankenstein, T.
Human Gene Therapy 8 : 1695-1700. 1 January 1997

Methods for use of cytokine gene-modified tumor cells in immunotherapy of cancer.
Qin, Z. and Blankenstein, T.
Methods in Molecular Medicine 7 : 339-348. 1997

Attenuation of collagen induced-arthritis in mice by treatment with vector cells engineered to secrete interleukin-13.
Bessis, N. and Boissie, M.C. and Ferrara, P. and Blankenstein, T. and Fradelizi, D. and Fournier, C.
European Journal of Immunology 26 : 2399-2403. 1 January 1996

Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant.
Cayeux, S. and Beck, C. and Doerken, B. and Blankenstein, T.
Human Gene Therapy 7 (4): 525-529. 1 January 1996

Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein.
Brocke, S. and Gijbels, K. and Allegretta, M. and Ferber, I. and Piercy, C. and Blankenstein, T. and Martin, R. and Utz, U. and Karin, N. and Mitchell, D. and Veromaa, T. and Waisman, A. and Gaur, A. and Conlon, P. and Ling, N. and Fairchild, P.J. and Wraith, D.C. and Ogarra, A. and Fathman, C.G. and Steinman, L.
Nature 379 (6563): 343-346. 1 January 1996

European school of oncology position paper - gene therapy for the medical oncologist.
Blaese, M. and Blankenstein, T. and Brenner, M. and Cohenhaguenauer, O. and Gansbacher, B. and Sorrentino, B. and Velu, T.
European Journal of Cancer 31A (9): 1531-1537. 1 January 1995

Human lymphotoxin has at least equal antitumor activity in comparison to human tumor necrosis factor but is less toxic in mice.
Qin, Z. and van Tits, L.J.H. and Buurman, W.A. and Blankenstein, T.
Blood 85 : 2779-2785. 1 January 1995

IL-10 converts mouse lymphoma cells to a CTL-resistant, nk-sensitive phenotype with low but peptide-inducible MHC class I expression.
Salazar-Onfray, F. and Petersson, M. and Franksson, L. and Matsuda, M. and Blankenstein, T. and Karre, K. and Kiessling, R.
Journal of Immunology 154 (12): 6291-6298. 1 January 1995

Influence of retrovirally transduced human tumor-necrosis-factor-alpha on the expression of C-myc, k-ras, C-jun, p53, tgf-alpha, and cea in human colon-carcinoma cell-lines.
Uckert, W. and Walther, W. and Hummel, O.
International Journal of Oncology 6 : 1027-1031. 1 January 1995

The rat interleukin-4 receptor: coevolution of ligand and receptor.
Richter, G. and Hein, G. and Blankenstein, T. and Diamantstein, T.
Cytokine 7 : 237-241. 1 January 1995

The thymidine kinase/ganciclovir-mediated "suicide" effect is highly variable in different tumor cells.
Beck, C. and Cayeux, S. and Lupton, S. and Doerken, B. and Blankenstein, T.
Human Gene Therapy 6 (12): 1525-1530. 1 January 1995

Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines.
Cayeux, S. and Beck, C. and Aicher, A. and Doerken, B. and Blankenstein, T.
European Journal of Immunology 25 (8): 2325-2331. 1 January 1995

Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response.
Qin, Z. and Blankenstein, T.
Cancer Research 55 (21): 4747-4751. 1 January 1995

Conditional expression of human TNF-alpha: a system for inducible cytotoxicity.
Sparmann, G. and Walther, W. and Guenzburg, W.H. and Uckert, W. and Salmons, B.
International Journal of Cancer 59 : 103-107. 1 January 1994

Expression of interleukin 10 in human melanoma.
Krueger-Krasagakes, S. and Krasagakis, K. and Garbe, C. and Schmitt, E. and Huels, C. and Blankenstein, T. and Diamantstein, T.
British Journal of Cancer 70 : 1182-1185. 1 January 1994

Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL- 10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants.
Allione, A. and Consalvo, M. and Nanni, P. and Lollini, P.L. and Cavallo, F. and Giovarelli, M. and Forni, M. and Gulino, A. and Colombo, M.P. and Dellabona, P. and Hock, H. and Blankenstein, T. and Rosenthal, F.M. and Gansbacher, B. and Bosco, M.C. and Musso, T. and Gusella, L. and Forni, G.
Cancer Research 54 : 6022-6026. 1 January 1994

Increasing tumour immunogenicity by genetic modification.
Blankenstein, T.
European Journal of Cancer 30A : 1182-1187. 1 January 1994

Influence of different promoters on the expression of tumor necrosis factor alpha in LS174T human colon carcinoma cells.
Uckert, W. and Asche, O. and Mahanty, B. and Fichtner, I.
International Journal of Oncology 5 : 865-871. 1 January 1994

Observations with tumour necrosis factor gene-transfected tumours.
Blankenstein, T.
Folia Biologica Prague 40 : 19-28. 1 January 1994

Tumor-cell-targeted cytokine gene transfer in experimental models for cancer therapy.
Hock, H. and Dorsch, M. and Richter, G. and Kunzendorf, U. and Krueger-Krasagakes, S. and Blankenstein, T. and Qin, Z.H. and Diamantstein, T.
Natural Immunity 13 : 85-92. 1 January 1994

Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration.
Richter, G. and Krueger-Krasagakes, S. and Hein, G. and Huels, C. and Schmitt, E. and Diamantstein, T. and Blankenstein, T.
Cancer Research 53 (18): 4134-4137. 15 September 1993

Lymphotoxin, tumour necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases.
Foss, H.D. and Herbst, H. and Oelmann, E. and Samol, J. and Grebe, M. and Blankenstein, T. and Matthes, J. and Qin, Z. and Falini, B. and Pileri, S. and Diamantstein, T. and Stein, H.
British Journal of Haematology 84 (4): 627-635. 1 August 1993

Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis.
Qin, Z. and Krueger-Krasagakes, S. and Kunzendorf, U. and Hock, H. and Diamantstein, T. and Blankenstein, T.
Journal of Experimental Medicine 178 (1): 355-360. 1 July 1993

Rapid method of total RNA mini-preparation from eucaryotic cells.
Walther, W. and Stein, U. and Uckert, W.
Nucleic Acids Research 21 (7): 1682. 11 April 1993

Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon-gamma.
Hock, H. and Dorsch, M. and Kunzendorf, U. and Qin, Z. and Diamantstein, T. and Blankenstein, T.
Proceedings of the National Academy of Sciences of the United States of America 90 (7): 2774-2778. 1 April 1993

Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant.
Hock, H. and Dorsch, M. and Kunzendorf, U. and Ueberla, K. and Qin, Z. and Diamantstein, T. and Blankenstein, T.
Cancer Research 53 (4): 714-716. 15 February 1993

Eosinophils infiltrating interleukin-5 gene-transfected tumors do not suppress tumor growth.
Krueger-Krasagakes, S. and Li, W. and Richter, G. and Diamantstein, T. and Blankenstein, T.
European Journal of Immunology 23 : 992-995. 1 January 1993

Humaner Tumor-Nekrose-Faktor-alpha: Konzentrationsbestimmung in Kulturueberstaenden mittels ELISA.
Asche, O. and Uckert, W.
Biochemica-Information 90 : 20-22. 1 January 1993

Macrophage colony-stimulating factor gene transfer into tumor cells induces macrophage infiltration but not tumor suppression.
Dorsch, M. and Hock, H. and Kunzendorf, U. and Diamantstein, T. and Blankenstein, T.
European Journal of Immunology 23 : 186-190. 1 January 1993

Retrovirus-mediated gene transfer of tumor necrosis factor alpha into colon carcinoma cells generates a growth inhibition.
Walther, W. and Fichtner, I. and Uckert, W.
Anticancer Research 13 : 1565-1574. 1 January 1993

Kinetic analysis of cytokine gene expression in the livers of naive and immune mice infected with Listeria monocytogenes. The immediate early phase in innate resistance and acquired immunity.
Ehlers, S. and Mielke, M.E. and Blankenstein, T. and Hahn, H.
Journal of Immunology 149 (9): 3016-3022. 1 November 1992

Abnormal TNF production in prediabetic BB rats is linked to defective CD45R expression.
Rothe, H. and Schuller, I. and Richter, G. and Jongeneel, C.V. and Kiesel, U. and Diamantstein, T. and Blankenstein, T. and Kolb, H.
Immunology 77 (1): 1-6. 1 January 1992

Analysis of cytokine mRNA levels in interleukin-4-transgenic mice by quantitative polymerase chain reaction.
Platzer, C. and Richter, G. and Ueberla, K. and Mueller, W. and Bloecker, H. and Diamantstein, T. and Blankenstein, T.
European Journal of Immunology 22 (5): 1179-1184. 1 January 1992

Interleukin-4-mediated tumor suppression in nude mice involves interferon-gamma.
Platzer, C. and Richter, G. and Ueberla, K. and Hock, H. and Diamantstein, T. and Blankenstein, T.
European Journal of Immunology 22 (7): 1729-1733. 1 January 1992

Inhibition of the TPA-induction of simian sarcoma virus by an antisense v-jun oncogene.
Stein, U. and Wunderlich, V. and Uckert, W.
Archiv fuer Geschwulstforschung 61 : 163-169. 1 January 1991

Book Section

The role of inflammation for tumour growth and tumour suppression.
Blankenstein, T.
In: Cancer and inflammation : Symposium on Cancer and Inflammation, held at the Novartis Foundation, London, 12-14 November 2002. Novartis Foundation Symposium ; 256 . Wiley, Hoboken, N.J., 205-210. ISBN 0-470-85510-X 23 January 2004

Green fluorescent protein retroviral vector. Generation of high-titer producer cells and virus supernatant.
Uckert, W. and Pedersen, L. and Guenzburg, W.
In: Gene Therapy of Cancer : Methods and Protocols. Methods in Molecular Medicine. ; 35 . Humana Press, Totowa,NJ, 275-285. 1 January 2000

Gene Therapy of Familial Hypercholesterolemia.
Cichon, G. and Strauss, M.
In: Gene therapy :Principles and Applications. Birkhaeuser, Basel, 151-167. ISBN 3-7643-5972-2 1 January 1999

Vaccines using gene-modified tumor cells.
Cayeux, S. and Qin, Z. and Doerken, B. and Blankenstein, T.
In: Gene therapy :Principles and Applications. Birkhaeuser, Basel, 283-298. ISBN 3-7643-5972-2 1 January 1999

Large and small scale RNA preparations from eukaryotic cells.
Uckert, W. and Walther, W. and Stein, U.
In: RNA Isolation and Characterization Protocols. Methods in Molecular Biology ; 86 . Humana Press, Totowa,NJ, 7-14. 1 January 1998

Tumor cell vaccines using genetically modified cells coexpressing cytokines and the T cell costimulatory molecule B7.
Cayeux, S. and Doerken, B. and Blankenstein, T.
In: Concepts in Gene Therapy. de Gruyter, Berlin [u.a.], 487-503. 1 January 1997

Polymerase chain reaction to quantitate cytokine mRNA.
Platzer, C. and Blankenstein, T.
In: Cytokines : A Practical Approach. Oxford University Press, New York, 57-68. 1 January 1995

Detection of cytokines induced by and involved in the anti-tumor response provoked by tumor cell derived interleukin-4.
Richter, G. and Platzer, C. and Blankenstein, T. and Diamantstein, T.
In: Cytokines in Cancer Therapy. Contributions to Oncology ; 46 . Karger, Basel, 281-285. 1 January 1994

Rejection of IL-7 gene transfected tumors.
Blankenstein, T. and Hock, H. and Dorsch, M. and Diamantstein, T.
In: Cytokine-Induced Tumor Immunogenicity: From Exogenous Molecules to Gene Therapy. Acad.Press, New York, 217-231. 1 January 1994

Tumor cell targeted IL7 gene transfer reveals T cell-dependent anti-tumor activity in vivo.
Hock, H. and Dorsch, M. and Blankenstein, T. and Diamantstein, T.
In: Cytokines in Cancer Therapy. Contributions to Oncology ; 46 . Karger, Basel, 277-280. 1 January 1994

Cytokine involvement in tumor development and tumor suppression.
Dorsch, M. and Diamantstein, T. and Blankenstein, T.
In: Cytokines in Hemopoiesis, Oncology, and AIDS II. Springer, Berlin, 87-92. 1 January 1993

Retroviral transduction of the human TNF alpha gene into tumour cells generates a growth inhibitory effect.
Walther, W. and Huth, J. and Sparmann, G. and Uckert, W.
In: European Biotechnology Today. INTERCEPT Ltd., Andover, 209-216. 1 January 1992

Book

Gene therapy :Principles and Applications.
Blankenstein, T.
Birkhaeuser, Basel. ISBN 3-7643-5972-2 1 January 1999

Patent

Construction of a T cell line-based packaging cell line for the production of T cell receptor retroviruses by enriching of Cd3 expressing cells.
Uckert, W. and Blankenstein, T.
WO0700318. 4 January 2007

Konditionales Immortalisationsverfahren fuer humane Tumorzellen zur Herstellung einer Vakzine.
Blankenstein, T. and Li, L.P.
DE19626830A1. 8 January 1999

Mittel zur Behandlung von Tumorerkrankungen durch Entfernen von B-Lymphozyten der Patienten.
Blankenstein, T. and Qin, Z.
DE19720154A1. 5 November 1998

Lebendvakzine zur Behandlung von Tumorerkrankungen [Live vaccine for the treatment of tumour diseases].
T. Blankenstein, S. Cayeux.
EP0777499A1 ; EP0777499B1 ; WO9605866A2 ; WO9605866A3 ; US6,039,941. 11 June 1997

Lebendvakzine gegen Tumorerkrankungen.
Blankenstein, T. and Cayeux-Pezzutto, S.
DE4431401A1. 29 February 1996

Review

Diverse effects of obesity on antitumor immunity and immunotherapy.
Dyck, L. and Lynch, L.
Trends in Molecular Medicine 29 (2): 112-123. February 2023

The role of CD4 T cells in rejection of solid tumors.
Poncette, L. and Bluhm, J. and Blankenstein, T.
Current Opinion in Immunology 74 : 18-24. February 2022

T cell receptors for clinical therapy: in vitro assessment of toxicity risk.
Kunert, A. and Obenaus, M. and Lamers, C.H.J. and Blankenstein, T. and Debets, R.
Clinical Cancer Research 23 (20): 6012-6020. 15 October 2017

Targeting cancer-specific mutations by T cell receptor gene therapy.
Blankenstein, T. and Leisegang, M. and Uckert, W. and Schreiber, H.
Current Opinion in Immunology 33 : 112-119. April 2015

The adaptive immune response to sporadic cancer.
Willimsky, G. and Blankenstein, T.
Immunological Reviews 220 (1): 102-112. December 2007

Do autochthonous tumors interfere with effector T cell responses?
Blankenstein, T.
Seminars in Cancer Biology 17 (4): 267-274. August 2007

Immunotherapy: target the stroma to hit the tumor.
Kammertoens, T. and Schueler, T. and Blankenstein, T.
Trends in Molecular Medicine 11 (5): 225-231. 1 January 2005

The role of tumor stroma in the interaction between tumor and immune system.
Blankenstein, T.
Current Opinion in Immunology 17 (2): 180-186. 1 January 2005

The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis.
Blankenstein, T. and Qin, Z.H.
Current Opinion in Immunology 15 (2): 148-154. April 2003

Chemical carcinogens as foreign bodies and some pitfalls regarding cancer immune surveillance.
Blankenstein, T. and Qin, Z.
Advances in Cancer Research 90 : 179-207. 2003

Suicide gene therapy for pediatric tumors.
Beltinger, C. and Uckert, W. and Debatin, K.M.
Journal of Molecular Medicine 78 (11): 598-612. 1 January 2001

Genetic approaches to cancer immunotherapy.
Blankenstein, T. and Cayeux, S. and Qin, Z.
Reviews of Physiology Biochemistry and Pharmacology 129 : 1-49. 1 January 1996

The influence of local cytokines on tumor metastasis: using cytokine gene transfected tumor cells as experimental models.
Qin, Z. and Blankenstein, T.
Current Topics in Microbiology and Immunology 213/III : 55-64. 1 January 1996

Vectors in cancer therapy: how will they deliver.
Blaese, M. and Blankenstein, T. and Brenner, M. and Cohen-Haguenauer, O. and Gansbacher, B. and Russell, S. and Sorrentino, B. and Velu, T.
Cancer Gene Therapy 2 (4): 291-297. 1 January 1995

Retrovirus-mediated gene transfer in cancer therapy.
Uckert, W. and Walther, W.
Pharmacology & Therapeutics 63 : 323-347. 1 January 1994

Letter

Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al.
Immisch, L. and Papafotiou, G. and Popp, O. and Mertins, P. and Blankenstein, T. and Willimsky, G.
Journal for ImmunoTherapy of Cancer 11 (3): e006784. 14 March 2023

Intracellular expression of FLT3 in Purkinje cells: implications for adoptive T-cell therapies.
Çakmak-Görür, N. and Radke, J. and Rhein, S. and Schumann, E. and Willimsky, G. and Heppner, F.L. and Blankenstein, T. and Pezzutto, A.
Leukemia 33 (4): 1039-1043. April 2019

A cancer immunosurveillance controversy.
Qin, Z.H. and Blankenstein, T.
Nature Immunology 5 (1): 3-4. 1 January 2004

Editorial

Editorial: Mitochondria as a hub in cellular signaling.
Stoolman, J.S. and Porcelli, A.M. and Martínez-Reyes, I.
Frontiers in Cell and Developmental Biology 10 : 981464. 15 August 2022

"Designer cytokines" targeting the tumor vasculature - think global and act local.
Kammertoens, T. and Kemna, J. and Leisegang, M.
EMBO Molecular Medicine 12 (2): e11801. 7 February 2020

Receptor combinations hone T-cell therapy.
Blankenstein, T.
Nature Biotechnology 34 (4): 389-391. 7 April 2016

Adoptive T-cell therapy to treat liver cancer: Is the liver microenvironment key?
Willimsky, G. and Protzer, U. and Knolle, P. and Heikenwalder, M.
Oncotarget 4 (8): 1117-1118. August 2013

It's the peptide-MHC affinity, stupid.
Kammertoens, T. and Blankenstein, T.
Cancer Cell 23 (4): 429-431. 15 April 2013

Cross-priming versus cross-tolerance: are two signals enough?
Blankenstein, T. and Schueler, T.
Trends in Immunology 23 (4): 171-173. 1 April 2002

Cancer vaccines in gene therapy.
Blankenstein, T. and Qin, Z.
Gene Therapy 3 (2): 95-96. 1 January 1996

Preprint

Identification and ranking of recurrent neo-epitopes in cancer.
Blanc, E. and Holtgrewe, M. and Dhamodaran, A. and Messerschmidt, C. and Willimsky, G. and Blankenstein, T. and Beule, D.
bioRxiv : 389437. 10 August 2018